argenx NV ADR (ARGX)vsDermata Therapeutics Inc (DRMA)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
DRMA
Dermata Therapeutics Inc
$1.55
-1.27%
HEALTHCARE · Cap: $4.67M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. DRMA trades at a lower P/E of 0.1x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
DRMA
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+98.6%
Fair Value
$103.63
Current Price
$1.55
$102.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : DRMA
The strongest argument for DRMA centers on P/E Ratio, Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while DRMA is a value play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.60 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 23/100), backed by strong 30.5% margins and 73.0% revenue growth. DRMA offers better value entry with a 98.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead asset, DMT310, which utilizes a novel delivery system to improve treatment efficacy for acne and other skin disorders. The company is committed to addressing significant unmet needs in the dermatology market with a strategically designed pipeline aimed at advancing skin health. As Dermata navigates its clinical trials, it leverages proprietary technology to create effective, safe, and user-friendly therapeutic solutions that position it for leadership in the dermatological arena. With a strong emphasis on patient outcomes, Dermata is poised to make a meaningful impact in the treatment of skin-related issues.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?